Tibet Aim Pharm., Inc. Class A

As of June 30, 2026, Tibet Aim Pharm., Inc. Class A carries a market capitalization of 2.87B, placing it among publicly traded companies globally. Its enterprise value stands at 2.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Tibet Aim Pharm., Inc. Class A has 190.68M shares outstanding.

As of June 30, 2026, Tibet Aim Pharm., Inc. Class A trades at a trailing price-to-earnings ratio of 28.90. The price-to-sales ratio is 4.15, and the price-to-book ratio stands at 3.32.

As of June 30, 2026, Tibet Aim Pharm., Inc. Class A trades at an EV/EBITDA multiple of 17.72 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.20B versus a market cap of 2.87B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tibet Aim Pharm., Inc. Class A maintains a current ratio of 2.41, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.33, indicating elevated leverage, while an interest coverage ratio of 204.39 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Tibet Aim Pharm., Inc. Class A posted a return on equity (ROE) of 11.85, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.38 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.82, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.41, useful for judging operating efficiency across full business cycles. The company generates approximately 1.66M in revenue per employee across its workforce of 404.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.77 indicates how many times Tibet Aim Pharm., Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Tibet Aim Pharm., Inc. Class A recorded 25.78M in income tax expense. That works out to an effective tax rate of 21.02, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 122.63M, leaving 96.26M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Tibet Aim Pharm., Inc. Class A's stock has declined approximately 16.79% over the past 52 weeks. The 50-day moving average sits at 17.28, while the 200-day moving average is 18.32.

Over the twelve months ended June 30, 2026, Tibet Aim Pharm., Inc. Class A generated 669.83M in revenue and converted that into 96.26M in net income, yielding earnings per share of 0.52. EBITDA reached 123.92M, while operating income came in at 120.21M.

As of June 30, 2026, Tibet Aim Pharm., Inc. Class A holds 699.34M in cash and equivalents against 28.80M in total debt, resulting in a net debt position of -470.54M. Total book value stands at 863.65M, with working capital of 462.44M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tibet Aim Pharm., Inc. Class A posted a gross margin of 81.97, reflecting its pricing power and cost economics. The operating margin of 17.95 and net profit margin of 14.37 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Tibet Aim Pharm., Inc. Class A paid dividends of 0.26 per share. The dividend payout ratio of 49.26 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tibet Aim Pharm., Inc. Class A shareholders.

As of June 30, 2026, Tibet Aim Pharm., Inc. Class A has an Altman Z-Score of 7.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.